Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta‐analysis of phase 3 trials in Japan
Abstract Introduction Considering that the efficacy results of the Japan lurasidone phase 3 trials for acute schizophrenia were inconsistent, we conducted a systematic review and a random‐effect model network meta‐analysis of those trials to examine whether lurasidone was beneficial for the treatmen...
Main Authors: | Taro Kishi, Tadashi Nosaka, Kenji Sakuma, Makoto Okuya, Nakao Iwata |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-09-01
|
Series: | Neuropsychopharmacology Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/npr2.12131 |
Similar Items
-
Lurasidone, olanzapine, and quetiapine extended‐release for bipolar depression: A systematic review and network meta‐analysis of phase 3 trials in Japan
by: Taro Kishi, et al.
Published: (2020-12-01) -
Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta‐analysis
by: Taro Kishi, et al.
Published: (2024-03-01) -
Efficacy and tolerability of lurasidone in schizophrenia: A systematic review and meta-analysis of short-term, randomized, placebo controlled trials
by: K. Hagi, et al.
Published: (2021-04-01) -
Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
by: Taro Kishi, et al.
Published: (2021-09-01) -
Schizophrenia relapse, patient considerations, and potential role of lurasidone
by: Citrome L
Published: (2016-08-01)